Clinical trial
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
NCT00430586 · Merz Pharmaceuticals GmbH, Industry · Completed
Key facts
| NCT number | NCT00430586 |
|---|---|
| Title | Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines |
| Official title | A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Determine the Optimal Dose of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines |
| Lead sponsor | Merz Pharmaceuticals GmbH, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glabellar Frown Lines |
| Intervention type | Drug |
| Interventions | Botulinum neurotoxin type A, free of complexing proteins, Placebo |
| Enrollment | 191 |
| Start date | Nov 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Feb 2, 2007 |
| Last update posted | Aug 3, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: